Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
This analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance) registry from 2004 to 2008. A total of 2,496 patients with non-albicans species of Candida isolates were identified. The identified species were C. glabrata (46.4%), C. parapsilosis (24.7%), C. tropicalis (13.9%), C. krusei (5.5%), C. lusitaniae (1.6%), C. dubliniensis (1.5%) and C. guilliermondii (0.4%); 111 infections involved two or more species of Candida (4.4%). Non-albicans species accounted for more than 50% of all cases of invasive candidiasis in 15 of the 24 sites (62.5%) that contributed more than one case to the survey. Among solid organ transplant recipients, patients with non-transplant surgery, and patients with solid tumors, the most prevalent non-albicans species was C. glabrata at 63.7%, 48.0%, and 53.8%, respectively. In 1,883 patients receiving antifungal therapy on day 3, fluconazole (30.5%) and echinocandins (47.5%) were the most frequently administered monotherapies. Among the 15 reported species, 90-day survival was highest for patients infected with either C. parapsilosis (70.7%) or C. lusitaniae (74.5%) and lowest for patients infected with an unknown species (46.7%) or two or more species (53.2%). In conclusion, this study expands the current knowledge of the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in North America. The variability in species distribution in these centers underscores the importance of local epidemiology in guiding the selection of antifungal therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“although C. glabrata has been reported to represent more than 30% of the non-albicans Candida in some geographic areas [4, 6–9].”
From Invasive candidiasis species distribution and trends, United States, 2009-2017 (2021) · cites this paper as [7]
In the citing paper
“C. glabrata bloodstream infections are commonly found in elderly individuals, diabetic patients and solid organ transplant recipients [6,8,9].”
From Candida glabrata: A Lot More Than Meets the Eye (2019) · cites this paper as [8]
In the citing paper
“The emergence of resistant strains, including those becoming resistant to multiple drugs, has been increasingly reported in recent years [14,15,16].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“More than 30 species of Candida have been reported to cause IC [3–6].”
BackgroundSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 2×
“parapsilosis, the early removal of central venous catheters remains an important principle in the management of candidemia caused by this species [29].”
BackgroundSelf-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331 · cited 1×
“from blood cultures and other forms of IC (proven or probable) were defined according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria [33].”
MethodCornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 4×
“On reviewing the approaches to antifungal therapy reported by the participating centers, several appear to be at odds with current consensus guidelines [28–30] and reported susceptibility profiles in the literature [14,21].”
BackgroundResultInfluentialEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901 · cited 2×
“7%, in keeping with other reports [1].”
BackgroundSelf-citationAndes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793 · cited 2×
“Indeed Andes et al [39] found in a patient-level T a b le 1 .”
BackgroundSelf-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 2×
“glabrata with co-resistance to both azoles and echinocandins in some medical centers [12,13,20].”
BackgroundSelf-citationThe changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758 · cited 2×
“glabrata has been reported by other investigators [23–27]; however, a recent systematic review by Falagas et al.”
BackgroundResultPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718 · cited 1×
“While some of these species have been designated as ‘emerging’ species, the apparent increased detection of these species may simply reflect the more vigorous efforts to identify clinical isolates of Candida to the species level in recent years [6,20,46].”
BackgroundSelf-citationPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694 · cited 3×
“4% of all N-CA isolates in this registry, there are several that merit attention either because they have been shown to cause clusters of infection in the hospital setting, because they are frequently misidentified by conventional methods or represent ‘cryptic’ species, or because they exhibit decreased susceptibility…”
BackgroundSelf-citationClancy, C. J., & Nguyen, M. H. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit006 · Cited by 688 · cited 2×
“The use of non-culture tests as biomarkers may prove to be useful adjuncts to blood culture, and identify some patients who are currently undiagnosed [68].”
BackgroundParczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656
Leroy, O., Gangneux, J.-P., Montravers, P., Mira, J.-P., Gouin, F., Sollet, J.-P., Carlet, J., Reynes, J., Rosenheim, M., Regnier, B., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819efac0 · Cited by 535
Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 394 · cited 2×
“Previously, we provided an overview of 3,648 cases of candidemia from the PATH Alliance database for the time period from July 1, 2004 to December 31, 2008 [8].”
BackgroundSelf-citationESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.
Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., Jensen, H. E., Lass-Flörl, C., Richardson, M. D., Akova, M., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12038 · Cited by 386 · cited 2×
“Current European Society of Clinical Microbiology and Infectious Disease guidelines recommend the b-D-glucan test, the mannan/anti-mannan test (candidemia only), and direct microscopy and histopathology as non-culture tests for diagnosis of IC [69].”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01747-08 · Cited by 370 · cited 1×
“tropicalis to fluconazole were seen among isolates from the Asia-Pacific region [44].”
BackgroundSelf-citationCleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
Lortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-10 · Cited by 362 · cited 1×
“parapsilosis as a cause of IC in patients pre-exposed to echinocandins [36,37].”
BackgroundFalagas, M. E., Roussos, N., & Vardakas, K. Z. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.04.006 · Cited by 346 · cited 2×
“Candida albicans is the most common species encountered in most settings [7].”
BackgroundUllmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
Hachem, R., Hanna, H., Kontoyiannis, D., Jiang, Y., & Raad, I. (2008) · Cancer · doi:10.1002/cncr.23466 · Cited by 331 · cited 1×
“krusei is best known for intrinsic resistance to fluconazole as well as its propensity to emerge in settings where fluconazole is used in prophylaxis [41,45].”
BackgroundFridkin, S. K., Kaufman, D., Edwards, J. R., Shetty, S., Horan, T., & Hospitals, T. N. N. I. S. S. (2006) · Pediatrics · doi:10.1542/peds.2005-1996 · Cited by 284
Sipsas, N. V., Lewis, R. E., Tarrand, J., Hachem, R., Rolston, K. V., Raad, I. I., & Kontoyiannis, D. P. (2009) · Cancer · doi:10.1002/cncr.24507 · Cited by 269 · cited 2×
“tropicalis [7,13,23,25,36,41–43,45], the apparent ‘‘emergence’’ of less common species may be due to a greater emphasis on species identification as a guide to initial treatment choices [28–30].”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Nagy, E., Dobiasova, S., Rinaldi, M., Barton, R., Veselov, A., & the Global Antifungal Surveillance Group (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01915-07 · Cited by 259
Self-citationKlotz, S. A., Chasin, B. S., Powell, B., Gaur, N. K., & Lipke, P. N. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.07.001 · Cited by 253 · cited 3×
“parapsilosis (24%) [65].”
ResultPfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N., & Castanheira, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00308-13 · Cited by 237
Self-citationNational Surveillance of Fungemia in Denmark (2004 to 2009)
Arendrup, M. C., Bruun, B., Christensen, J. J., Fuursted, K., Johansen, H. K., Kjældgaard, P., Knudsen, J. D., Kristensen, L., Møller, J., Nielsen, L., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01811-10 · Cited by 223
Candida parapsilosis Is a Significant Neonatal Pathogen: A Systematic Review and Meta-analysis
Pammi, M., Holland, L., Butler, G., Gacser, A., & Bliss, J. M. (2013) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182863a1c · Cited by 206 · cited 1×
“parapsilosis [34].”
Pfaller, M. A., Diekema, D. J., Mendez, M., Kibbler, C., Erzsebet, P., Chang, S.-C., Gibbs, D. L., Newell, V. A., & the Global Antifungal Surveillance Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00865-06 · Cited by 194 · cited 2×
“guilliermondii is known to exhibit decreased susceptibility to amphotericin B, fluconazole, and the echinocandins [14,16,54].”
BackgroundSelf-citationDesnos-Ollivier, M., Ragon, M., Robert, V., Raoux, D., Gantier, J.-C., & Dromer, F. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01451-08 · Cited by 154 · cited 1×
“guilliermondii is very difficult as these two species share many of the same biochemical and morphological features [60,61].”
BackgroundIncreasing incidence of Candida parapsilosis candidemia with caspofungin usage.
Forrest, G. N., Weekes, E., & Johnson, J. K. (2008) · Journal of Infection · doi:10.1016/j.jinf.2007.10.014 · Cited by 144 · cited 1×
“parapsilosis as a cause of IC in patients pre-exposed to echinocandins [36,37].”
BackgroundShifting patterns in the epidemiology of nosocomial Candida infections
Snydman, D. R. (2003) · Chest · doi:10.1378/chest.123.5_suppl.500s · Cited by 142 · cited 1×
“glabrata has been reported by other investigators [23–27]; however, a recent systematic review by Falagas et al.”
ResultGlobal trends in candidemia: Review of reports from 1995–2005
Morgan, J. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0044-7 · Cited by 139
Pfaller, M. A., Messer, S. A., Gee, S., Joly, S., Pujol, C., Sullivan, D. J., Coleman, D. C., & Soll, D. R. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.870-872.1999 · Cited by 137 · cited 1×
“dubliniensis from cases of oropharyngeal candidiasis in the pre-HAART era [52], subsequent studies have found most isolates to be susceptible to fluconazole, the newer azoles, as well as the echinocandins [14,53].”
BackgroundSelf-citationHope, W. W., Morton, A., & Eisen, D. P. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1131 · Cited by 130
Pfaller, M. A., Messer, S. A., Hollis, R. J., Boyken, L., Tendolkar, S., Kroeger, J., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00946-09 · Cited by 129
Self-citationDiekema, D. J., Messer, S. A., Boyken, L. B., Hollis, R. J., Kroeger, J., Tendolkar, S., & Pfaller, M. A. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00942-09 · Cited by 125 · cited 6×
“4% of all N-CA isolates in this registry, there are several that merit attention either because they have been shown to cause clusters of infection in the hospital setting, because they are frequently misidentified by conventional methods or represent ‘cryptic’ species, or because they exhibit decreased susceptibility…”
BackgroundResultSelf-citationFernández-Ruiz, M., Aguado, J. M., Almirante, B., Lora-Pablos, D., Padilla, B., Puig-Asensio, M., Montejo, M., García-Rodríguez, J., Pemán, J., Ruiz Pérez de Pipaón, M., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu158 · Cited by 122 · cited 2×
“Conversely, a recent study by Fernandez-Ruiz et al [40] found that the initial use of an echinocandin for treatment of IC due to C.”
ResultYang, Y.-L., Ho, Y.-A., Cheng, H.-H., Ho, M., & Lo, H.-J. (2004) · Infection Control & Hospital Epidemiology · doi:10.1086/502294 · Cited by 119 · cited 1×
“tropicalis from a variety of specimen types [43], and these data are supported by global surveillance data showing that the highest rates of resistance among C.”
BackgroundColombo, A. L., Melo, A. S. D. A., Rosas, R., Salomão, R., Briones, M. R. S., Hollis, R. J., Messer, S. A., & Pfaller, M. A. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(03)00079-8 · Cited by 118 · cited 1×
“rugosa is notable for causing nosocomial clusters of fungemia [62,63] and for decreased susceptibility to both azoles and echinocandins [15].”
BackgroundSelf-citationCandida dubliniensis: Ten years on
Sullivan, D. J., Moran, G. P., & Coleman, D. C. (2005) · FEMS Microbiology Letters · doi:10.1016/j.femsle.2005.09.015 · Cited by 118
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ng, K. P., Colombo, A., Finquelievich, J., Barnes, R., & Wadula, J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02122-07 · Cited by 108
Self-citationChapeland-Leclerc, F., Hennequin, C., Papon, N., Noël, T., Girard, A., Socié, G., Ribaud, P., & Lacroix, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01138-09 · Cited by 104 · cited 1×
“glabrata to develop antifungal resistance [22].”
Gales, A. C., Pfaller, M. A., Houston, A. K., Joly, S., Sullivan, D. J., Coleman, D. C., & Soll, D. R. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.12.3804-3808.1999 · Cited by 103 · cited 1×
“albicans by non-molecular methods [51].”
Self-citationPfaller, M. A., Diekema, D. J., Colombo, A. L., Kibbler, C., Ng, K. P., Gibbs, D. L., Newell, V. A., & the Global Antifungal Surveillance Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00863-06 · Cited by 99 · cited 1×
“rugosa is notable for causing nosocomial clusters of fungemia [62,63] and for decreased susceptibility to both azoles and echinocandins [15].”
BackgroundSelf-citationLockhart, S. R., Messer, S. A., Gherna, M., Bishop, J. A., Merz, W. G., Pfaller, M. A., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.02315-08 · Cited by 99 · cited 1×
“Although conventional phenotypic methods for identification work well for the common species of Candida, they are unable to differentiate among cryptic species within any of the species complexes [9,10] and are not reliable for the identification of less common species where nucleic acid sequencing and proteomic metho…”
BackgroundSelf-citationCandida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome
Atkinson, B. J., Lewis, R. E., & Kontoyiannis, D. P. (2008) · Medical Mycology · doi:10.1080/13693780801968571 · Cited by 98 · cited 2×
“[47] reported that, in contrast to patients with fungemia due to C.”
BackgroundResultCastanheira, M., Woosley, L. N., Diekema, D. J., Jones, R. N., & Pfaller, M. A. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01686-12 · Cited by 98 · cited 1×
“guilliermondii is very difficult as these two species share many of the same biochemical and morphological features [60,61].”
BackgroundSelf-citationHorn, D. L., Fishman, J. A., Steinbach, W. J., Anaissie, E. J., Marr, K. A., Olyaei, A. J., Pfaller, M. A., Weiss, M. A., Webster, K. M., & Neofytos, D. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.06.008 · Cited by 97 · cited 6×
“The Prospective Antifungal Therapy (PATH) Alliance registry was established in 2004, with 25 tertiary care medical centers in the US and Canada prospectively entering consecutive invasive fungal infections (IFIs) into a central database, in an effort to provide a more detailed description of the epidemiology and outco…”
MethodSelf-citationColeman, D. C., Sullivan, D. J., Harrington, B. J., Haynes, K., Henman, M. C., Shanley, D. B., Bennett, D. E., Moran, G. P., McCreary, C., & O'Neill, L. C. (1997) · Oral Diseases · doi:10.1111/j.1601-0825.1997.tb00384.x · Cited by 95 · cited 1×
“dubliniensis from cases of oropharyngeal candidiasis in the pre-HAART era [52], subsequent studies have found most isolates to be susceptible to fluconazole, the newer azoles, as well as the echinocandins [14,53].”
BackgroundPulimood, S., Ganesan, L. P., Alangaden, G. J., & Chandrasekar, P. H. (2002) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00460-1 · Cited by 91 · cited 1×
“Polyfungal IC is an uncommon nosocomial entity occurring in non-oncologic patients with multiple co-morbidities and heavy Candida colonization [64].”
BackgroundPfaller, M. A., Woosley, L. N., Messer, S. A., Jones, R. N., & Castanheira, M. (2012) · Mycopathologia · doi:10.1007/s11046-012-9551-x · Cited by 89 · cited 5×
“While some of these species have been designated as ‘emerging’ species, the apparent increased detection of these species may simply reflect the more vigorous efforts to identify clinical isolates of Candida to the species level in recent years [6,20,46].”
BackgroundSelf-citationPfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L. B., Hollis, R. J., & Jones, R. N. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.09.009 · Cited by 87 · cited 1×
“kefyr exhibit high minimum inhibitory concentrations when tested with amphotericin B [14,57].”
BackgroundSelf-citationFungemia and Colonization with Nystatin-Resistant Candida rugosa in a Burn Unit
Dube, M. P., Heseltine, P. N. R., Rinaldi, M. G., Evans, S., & Zawacki, B. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.1.77 · Cited by 86
Savini, V., Catavitello, C., Onofrillo, D., Masciarelli, G., Astolfi, D., Balbinot, A., Febbo, F., D’Amario, C., & D’Antonio, D. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01960.x · Cited by 84
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Barton, R., Bijie, H., Bille, J., Chang, S.-C., da Luz Martins, M., Duse, A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.01.002 · Cited by 80
Self-citationCandida dubliniensis: an emerging opportunistic pathogen.
Sullivan, D. J., & Coleman, D. C. (1997) · PubMed · Cited by 75
Changing spectrum of invasive candidiasis and its therapeutic implications
Singh, N. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00004.x · Cited by 71 · cited 1×
“glabrata has been reported by other investigators [23–27]; however, a recent systematic review by Falagas et al.”
ResultRisk factors for and clinical implications of mixed Candida/bacterial bloodstream infections
Kim, S.-H., Yoon, Y. K., Kim, M. J., & Sohn, J. W. (2013) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03906.x · Cited by 67 · cited 1×
“Mortality is reported to be similar to that seen with monomicrobial IC, but less than that seen with polymicrobial bacteremia [64–66].”
ResultTreatment of Candida famata bloodstream infections: case series and review of the literature
Beyda, N. D., Chuang, S. H., Alam, M. J., Shah, D. N., Ng, T. M., McCaskey, L. A., & Garey, K. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks388 · Cited by 62 · cited 2×
“guilliermondii marked by decreased susceptibility to both echinocandins and azoles [10,59].”
BackgroundRare and emerging Candida species
Johnson, E. M. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0020-z · Cited by 57 · cited 2×
“While some of these species have been designated as ‘emerging’ species, the apparent increased detection of these species may simply reflect the more vigorous efforts to identify clinical isolates of Candida to the species level in recent years [6,20,46].”
BackgroundRapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin
Fekkar, A., Meyer, I., Brossas, J. Y., Dannaoui, E., Palous, M., Uzunov, M., Nguyen, S., Leblond, V., Mazier, D., & Datry, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02037-12 · Cited by 56 · cited 1×
“More recently, resistance to echinocandins was documented in a strain emerging during caspofungin treatment [58].”
BackgroundReuter, C. W., Morgan, M. A., Bange, F., Gunzer, F., Eder, M., Hertenstein, B., & Ganser, A. (2005) · Clinical Infectious Diseases · doi:10.1086/497079 · Cited by 49 · cited 1×
“kefyr has been called an ‘emerging’ pathogen in patients with leukemia and neutropenia based on two reports documenting nosocomial BSI and colonization [55,56].”
BackgroundLockhart, S. R., Messer, S. A., Pfaller, M. A., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01889-08 · Cited by 41 · cited 3×
“Although conventional phenotypic methods for identification work well for the common species of Candida, they are unable to differentiate among cryptic species within any of the species complexes [9,10] and are not reliable for the identification of less common species where nucleic acid sequencing and proteomic metho…”
BackgroundSelf-citationMcClenny, N. B., Fei, H., Baron, E. J., Gales, A. C., Houston, A., Hollis, R. J., & Pfaller, M. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1325-1328.2002 · Cited by 39 · cited 1×
“course of therapy and may manifest as breakthrough infection in immunocompromised patients on amphotericin B therapy [4,47,48], Atkinson et al.”
BackgroundSelf-citationDevelopment of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment.
Desnos-Ollivier, M., Moquet, O., Chouaki, T., Guérin, A.-M., & Dromer, F. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00325-11 · Cited by 37 · cited 1×
“lusitaniae remains susceptible to both the triazoles and the echinocandins, although acquired resistance to the latter group of agents has been reported [14,21,49].”
BackgroundIs Candida kefyr an Emerging Pathogen in Patients with Oncohematological Diseases?
Sendid, B., Lacroix, C., & Bougnoux, M. (2006) · Clinical Infectious Diseases · doi:10.1086/506573 · Cited by 37 · cited 1×
“kefyr has been called an ‘emerging’ pathogen in patients with leukemia and neutropenia based on two reports documenting nosocomial BSI and colonization [55,56].”
BackgroundThe Epidemiology of Invasive Candidiasis
Pfaller, M. A., & Diekema, D. J. (2014) · Candida and Candidiasis · doi:10.1128/9781555817176.ch29 · Cited by 33
Self-citationReboli, A. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu160 · Cited by 8
Self-citation
Research works printed but not linked: 1
- D Horn, 2007, Contemporary patterns in the use of antifungal agents in the treatment of invasive fungal infections: perspectives from registries and databases, Curr Fungal Infect Rep, 1, 72
Cited by
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Self-citationThe Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
Antimicrobial Agents and Chemotherapy
(2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac · Cited by 485
de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
“Candida species, opportunistic pathogens, are a major cause of morbidity and mortality worldwide and thus represents a serious threat to public health (Pfaller et al., 2014; Matthaiou et al., 2015; Pappas et al., 2016).”
Background
Metadata
- Authors
- Pfaller, M. A., Andes, D. R., Diekema, D. J., Horn, D. L., Reboli, A. C., Rotstein, C., Franks, B., & Azie, N. E.
- Affiliations
- University of Iowa (US)
- University of Wisconsin–Madison (US)
- Cooper Medical School of Rowan University (US)
- University of Toronto (CA)
- Astellas Pharma (United States) (US)
- Corresponding author
- Pfaller, Michael A.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-03
- Volume
- 9
- Issue
- 7
- Pages
- e101510
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4081561
- OpenAlex
- W2053909542
- Cited by
- 396
- References
- 69
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 21 · 2023: 33 · 2022: 34 · 2021: 33 · 2020: 47 · 2019: 48 · 2018: 41 · 2017: 43 · 2016: 39 · 2015: 34 · 2014: 4
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer
- Massachusetts General Hospital
- University of Nebraska Medical Center
- University of Miami
- University of Pennsylvania
- Emory University
- Bunning Food Allergy Institute, Ann and Robert H. Lurie Children's Hospital of Chicago
- University of Minnesota
- University of Washington
- Johns Hopkins University
- University of Pittsburgh
- Hamilton Health Sciences
- Thomas Jefferson University
- University of Arkansas for Medical Sciences
- City of Hope
- Astellas Pharma
- University of Texas MD Anderson Cancer Center
- Medical Center, University of Pittsburgh
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- invasive candidiasis, non-albicans Candida, Candida glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Candida lusitaniae, Candida dubliniensis, Candida guilliermondii, Candida species distribution, antifungal therapy, fluconazole, echinocandins, 90-day survival, solid organ transplant recipients, solid tumors
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Antifungal Agents, Candida, Child, Child, Preschool, Drug Therapy, Combination, Female, Humans, Infant, Male, Middle Aged, Prospective Studies, Registries, Fluconazole, Prevalence, Survival Rate, Treatment Outcome, Echinocandins, Young Adult, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
